Castle Creek Biosciences, LLC.
Quick facts
Phase 3 pipeline
- D-Fi
D-Fi is a monoclonal antibody that targets an unspecified mechanism.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: